Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) declared a fourth-quarter 2025 dividend of $1.50 per share on outstanding common stock.

The dividend is payable on December 10, 2025 to shareholders of record at the close of business on November 14, 2025.

Eli Lilly (NYSE: LLY) announced on Oct 27, 2025 a nationwide partnership with Shaquille O'Neal to expand the "Don't Sleep on OSA" campaign and raise awareness of moderate-to-severe obstructive sleep apnea (OSA).

The initiative highlights that an estimated 24 million U.S. adults may have OSA, outlines common symptoms (loud snoring, choking/gasping, daytime sleepiness), and directs people to DontSleepOnOSA.com to learn more and talk to their healthcare provider.

Eli Lilly (NYSE: LLY) reported Phase 3b LUCENT-URGE results showing early, sustained improvement in bowel urgency for adults with moderately to severely active ulcerative colitis treated with Omvoh (mirikizumab‑mrkz).

Key outcomes: 55% reduction in daily bowel urgency episodes by Week 12 (maintained at Week 28), 52% reduction in urgency severity by Week 28, and increase in patients able to delay a bowel movement ≥15 minutes from 4.1% at baseline to 29.7% at Week 28. Safety was consistent with prior LUCENT data: 5.2% serious adverse events and 4.7% discontinuations due to adverse events. Results will be presented at ACG Oct 24–29, 2025.

Eli Lilly (NYSE:LLY) agreed to acquire Adverum Biotechnologies for $3.56 cash per share plus one CVR, with the CVR payable up to $8.91 for total potential consideration of $12.47 per share. The deal funds a tender offer and a second-step merger, is expected to close in Q4 2025, and requires a majority tender. Lilly provided a secured $65 million promissory note to support Adverum operations pre-close. Adverum's lead asset, Ixo-vec, is a Phase 3 intravitreal gene therapy for wet AMD (ARTEMIS trial completed screening) with Fast Track, RMAT, EMA PRIME, and UK Innovation Passport designations.

Lilly (NYSE: LLY) reported 52-week Phase 3 BRAVE-AA-PEDS results showing once-daily oral baricitinib 4 mg produced substantial hair regrowth in adolescents (ages 12 to <18) with severe alopecia areata.

Key one-year outcomes: 54.1% achieved ≥80% scalp hair coverage (SALT ≤20) on 4 mg versus 31% on 2 mg; 41.2% on 4 mg achieved ≥90% scalp coverage (SALT ≤10). In the severe-disease subgroup (SALT 50–94), 71% on 4 mg achieved successful regrowth. Eyebrow and eyelash regrowth rates were also higher on 4 mg. Safety was consistent with prior trials; no deaths, opportunistic infections, MACEs, or VTEs were reported.

Lilly plans to submit these adolescent data to global regulators for a potential label update for Olumiant and to enroll younger children in BRAVE-AA-PEDS.

Eli Lilly (NYSE: LLY) reported Phase 3 ADjoin extension data on Oct. 24, 2025 showing EBGLYSS (lebrikizumab-lbkz) maintained high disease control when switched from monthly maintenance dosing to a single 250 mg injection every eight weeks (Q8W).

Key results: EASI-75 rates were 79% Q8W vs 86% Q4W; IGA 0,1 rates were 62% Q8W vs 73% Q4W. No new safety signals or increased immunogenicity were observed. Lilly submitted these data to the FDA seeking a potential label update to offer an every-eight-week maintenance option; an every-twelve-week study is underway.

Lilly (NYSE: LLY) announced primary overall survival results from the Phase 3 monarchE trial showing two years of adjuvant Verzenio (abemaciclib) plus endocrine therapy reduced the risk of death by 15.8% versus endocrine therapy alone (7-year OS: 86.8% vs 85.0%; HR 0.842; 95% CI 0.722–0.981; 2-sided p=0.027) with median follow-up of 6.3 years. The regimen also showed sustained benefits in invasive disease-free survival and distant relapse-free survival, and 32% fewer patients were living with metastatic disease (6.4% vs 9.4%). Safety was consistent with prior analyses; data were published in Annals of Oncology and presented at ESMO on Oct 17, 2025.

Eli Lilly (NYSE: LLY) will release its third-quarter 2025 financial results on October 30, 2025.

The company will host a conference call for investors and media on the same day beginning at 10:00 a.m. Eastern time, with a live webcast and a replay available via the investor website at https://investor.lilly.com/webcasts-and-presentations.

Eli Lilly (NYSE: LLY) reported positive topline Phase 3 results for oral GLP-1 orforglipron from ACHIEVE-2 and ACHIEVE-5 on Oct 15, 2025. At week 40, orforglipron doses (3 mg, 12 mg, 36 mg) met primary and all key secondary endpoints for both efficacy and treatment-regimen estimands, delivering meaningful A1C reductions and weight loss versus comparators.

Key numeric results: ACHIEVE-2 A1C change vs dapagliflozin (efficacy estimand) was -1.3%/ -1.7%/ -1.7% (3/12/36 mg) vs -0.8%; ACHIEVE-5 with insulin glargine showed -1.5%/ -2.1%/ -1.9% vs -0.8% for placebo. Safety was consistent with prior studies; common adverse events were GI-related and generally mild-to-moderate.

Lilly expects ACHIEVE-4 readout in Q1 2026 and plans regulatory submissions for type 2 diabetes in 2026; obesity submission remains on track for year-end.